VELSIPITY Sales Forecast, and Market Size Analysis – 2034

Key Factors Driving VELSIPITY Growth

1. Expanding Regulatory Approvals and Global Launches

• VELSIPITY received US FDA approval in October 2023 for adults with moderately to severely active ulcerative colitis (UC), marking it as an important oral advanced therapy option in a historically injectable-dominated space. The approval was based on strong Phase III data showing significant clinical remission and favorable safety outcomes.
• Following US approval, European Commission authorization (2024) enabled use in patients 16 years and older across the EU, broadening geographic reach.
• Recent approval in China by the National Medical Products Administration (NMPA) in February 2026 opens one of the world’s fastest-growing UC markets — especially relevant given projections that UC prevalence in China could rise from ~0.98 million in 2025 to ~1.5 million by 2031.
• Additional regulatory progress is underway in Taiwan, South Korea, and other Asian markets, enhancing future patient access and commercial opportunity.

2. Strong Clinical Differentiators and Guideline Inclusion

• VELSIPITY’s mechanism as a selective sphingosine-1-phosphate (S1P) receptor modulator offers an oral once-daily option with steroid-free remission and mucosal healing benefits — a major preference for patients reluctant to use injectables or infused biologics.
• Its clinical benefit is supported by multiple Phase III programs (ELEVATE UC 52, ELEVATE UC 12, ENLIGHT UC) showing statistically significant and clinically meaningful improvements across induction and maintenance endpoints (including mucosal healing of ~51.9% at Week 40 in the ENLIGHT Asian study).
• Because of robust data, VELSIPITY has been included in influential clinical guidelines like the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) updates, recommending it for both induction and maintenance of remission — reinforcing clinician confidence.

3. Penetration into High-Growth Markets, Particularly Asia

• VELSIPITY’s approvals in Asia (Macau, Singapore, and recently China) and impending submissions in Taiwan and South Korea reflect a regional expansion strategy in markets where UC prevalence and awareness are rising — especially China.
• Launches under policies like the Guangdong-Hong Kong-Macao “Connect Policy” help early uptake in key hospitals.

4. Growing Ulcerative Colitis Treatment Market

• The global ulcerative colitis drug market is rapidly expanding. Estimates show the market was ~USD 9.5 billion in 2025 and is projected to reach ~USD 14.8 billion by 2032 at a CAGR of ~6.5% — driven by novel targeted therapies like S1P modulators, JAK inhibitors, and IL-23/IL-12 agents.
• Other projections estimate the UC market could grow from ~USD 8.2 billion in 2024 to ~USD 12.5 billion by 2033 (~4.8% CAGR).

5. Commercial Forecasts and Peak Sales Potential

• Industry observers widely expect VELSIPITY to become a blockbuster product for Everest Medicines, with analysts projecting peak annual sales up to ~RMB 5 billion (~USD 700 million) in China alone once fully commercialized.
• Everest’s broader corporate revenue targets (including VELSIPITY) aim for >RMB 15 billion (~USD 2.1 billion) by 2030 across the company’s portfolio, with CAGR >50% 2025–2030 — highlighting VELSIPITY’s expected contribution.

6. Competitive Positioning and Unmet Need

• VELSIPITY competes in a landscape with other advanced therapies (e.g., IL-23 inhibitors like Omvoh and existing biologics), but its oral dosing and favorable safety profile help differentiate it, particularly for patients seeking convenient or non-injectable therapies.
• UC patients globally continue to experience unmet needs — many fail conventional treatments and seek durable remission — positioning VELSIPITY as a compelling option.

VELSIPITY Recent Developments

• In February 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
• In March 2024, The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (VELSIPITY) to treat people with moderately to severely active ulcerative colitis.
• In April 2024, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for VELSIPITY™. A once-daily oral treatment, VELSIPITY is for adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment. Ulcerative Colitis (UC) is the most common form of inflammatory bowel disease (IBD). In 2023, there are approximately 320,000 Canadians living with IBD, which includes Crohn’s disease and UC. IBD is characterized by chronic inflammation of the gastrointestinal (GI) tract and can have significant impact on a patient’s overall quality of life.

“VELSIPITY Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of VELSIPITY for approved indication like Ulcerative colitis; as well as potential indications like Atopic dermatitis and Eosinophilic oesophagitis in the 7MM. A detailed picture of VELSIPITY’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the VELSIPITY for approved and potential indications. The VELSIPITY market report provides insights about VELSIPITY’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current VELSIPITY performance, future market assessments inclusive of the VELSIPITY market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of VELSIPITY sales forecasts, along with factors driving its market.

VELSIPITY Drug Summary

VELSIPITY (etrasimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or intolerance to conventional therapy or biologic agents. Developed by Pfizer, it selectively binds S1P receptor subtypes 1, 4, and 5 to prevent lymphocyte egress from lymph nodes, reducing gut inflammation and achieving clinical remission (up to 27% at week 12 vs. 15% placebo in ELEVATE UC 52 trial), endoscopic improvement, histologic remission, and sustained benefits through 52 weeks, with once-daily 2 mg tablets (etrasimod arginine equivalent) containing inactive ingredients like mannitol, microcrystalline cellulose, and a colored film coating. FDA-approved in 2024 with required pre-treatment assessments (e.g., cardiac monitoring due to transient bradycardia risk, especially first dose), vaccinations, and screening for infections, it offers a favorable safety profile with mostly mild-to-moderate adverse events (e.g., headache, worsening UC, infections <5%), low serious infection rates (1.9%), and no increased malignancy or PML risk in trials. EMA-authorized for patients ≥16 years, it represents the newest oral S1P modulator in its class for UC. The report provides VELSIPITY’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the VELSIPITY Market Report

The report provides insights into:

• A comprehensive product overview including the VELSIPITY MoA, description, dosage and administration, research and development activities in approved indications like Ulcerative colitis; as well as potential indications like Atopic dermatitis and Eosinophilic oesophagitis.
• Elaborated details on VELSIPITY regulatory milestones and other development activities have been provided in VELSIPITY market report.
• The report also highlights VELSIPITY‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The VELSIPITY market report also covers the patents information, generic entry and impact on cost cut.
• The VELSIPITY market report contains current and forecasted VELSIPITY sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The VELSIPITY market report also features the SWOT analysis with analyst views for VELSIPITY in approved and potential indications.

Methodology

The VELSIPITY market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VELSIPITY Analytical Perspective by DelveInsight

• In-depth VELSIPITY Market Assessment

This VELSIPITY sales market forecast report provides a detailed market assessment of VELSIPITY for approved indication like Ulcerative colitis; as well as potential indications like Atopic dermatitis and Eosinophilic oesophagitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted VELSIPITY sales data uptil 2034.

• VELSIPITY Clinical Assessment

The VELSIPITY market report provides the clinical trials information of VELSIPITY for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

VELSIPITY Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

VELSIPITY Market Potential & Revenue Forecast

• Projected market size for the VELSIPITY and its key indications
• Estimated VELSIPITY sales potential (VELSIPITY peak sales forecasts)
• VELSIPITY Pricing strategies and reimbursement landscape

VELSIPITY Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• VELSIPITY Market positioning compared to existing treatments
• VELSIPITY Strengths & weaknesses relative to competitors

VELSIPITY Regulatory & Commercial Milestones

• VELSIPITY Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

VELSIPITY Clinical Differentiation

• VELSIPITY Efficacy & safety advantages over existing drugs
• VELSIPITY Unique selling points

VELSIPITY Market Report Highlights

• In the coming years, the VELSIPITY market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The VELSIPITY companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VELSIPITY’s dominance.
• Other emerging products for Ulcerative colitis; as well as potential indications like Atopic dermatitis and Eosinophilic oesophagitis are expected to give tough market competition to VELSIPITY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VELSIPITY in approved and potential indications.
• Analyse VELSIPITY cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted VELSIPITY sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of VELSIPITY in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of VELSIPITY? How strong is VELSIPITY’s clinical and commercial performance?
• What is VELSIPITY’s clinical trial status in each individual indications such as Ulcerative colitis; as well as potential indications like Atopic dermatitis and Eosinophilic oesophagitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VELSIPITY Manufacturers?
• What are the key designations that have been granted to VELSIPITY for approved and potential indications? How are they going to impact VELSIPITY’s penetration in various geographies?
• What is the current and forecasted VELSIPITY market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of VELSIPITY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to VELSIPITY for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is VELSIPITY? What is the duration of therapy and what are the geographical variations in cost per patient?

Show more